A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy
Boehringer Ingelheim
Boehringer Ingelheim
Jiangsu HengRui Medicine Co., Ltd.
Novartis
ITM Solucin GmbH
RayzeBio, Inc.
Crinetics Pharmaceuticals Inc.
Hoffmann-La Roche
Advanced Accelerator Applications
Novartis
Amgen
Camurus AB
Exelixis
Sanofi
ITM Solucin GmbH
Sinotau Pharmaceutical Group
Corcept Therapeutics
Jiangsu HengRui Medicine Co., Ltd.
Novartis
Astellas Pharma Inc
Ipsen
Sanofi
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Novartis
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Hutchmed
Hutchmed
Radiomedix, Inc.
Taizhou Hanzhong biomedical co. LTD
Ipsen
Ipsen
Ipsen
Advanced Accelerator Applications
Eisai Inc.
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Novartis
Novartis
Ipsen
Novartis
AstraZeneca
GE Healthcare
Amgen
Novartis
Novartis
Novartis
Sanofi
Novartis
Mateon Therapeutics
Corcept Therapeutics
Corcept Therapeutics
INSYS Therapeutics Inc